Skip to main content
  1. Home
  2. Emerging Tech
  3. News

NASA preps for seven-year journey to sample a near-Earth asteroid

Add as a preferred source on Google

You can add asteroid retrieval to NASA’s growing repertoire of space exploration skills. The space agency last week announced that it is preparing to embark on a seven-year mission to retrieve a piece of an asteroid. It will be NASA’s first mission that will return an asteroid sample for analysis. If all goes as planned, the asteroid chunk will be transported back to earth in 2023 for detailed analysis by researchers at NASA and the University of Arizona.

The mission will be powered by the Origins, Spectral Interpretation, Resource Identification, Security-Regolith Explorer (OSIRIS-REx) spacecraft. Designed and manufactured by Lockheed Martin, the spacecraft was built from the ground up for asteroid retrieval. It features Touch-and-Go Sample Acquisition Mechanism (TAGSAM) that uses a reverse vacuum to stir up asteroid dust for collection. The mechanism can collect up to 70 ounces of material in a ring-shaped canister. It also can study the asteroid in situ before sampling using a suite of instrumentation that includes visible-light cameras, infrared spectrometers, an x-ray spectrometer and an active-scanning lidar.

Recommended Videos

Nasa plans to launch the OSIRIS-REx during the launch window that begins on September 8. The spacecraft will be propelled into space using an Atlas V411 rocket and maneuver towards the Bennu asteroid. The spacecraft will travel up to 509 million miles to intercept the asteroid and will move along with it during sampling. The spacecraft will then return to Earth, traveling a total of 4.4 billion miles in the round trip journey.

When it enters the Earth’s atmosphere, the Sample Return Capsule will hit 27,700 mph, making it the second-fastest man-made object to travel back to earth. Scientist hopes the data collected from the asteroid will provide insight into the formation of the planets as well as help scientists understand the nature or near-Earth asteroids.

Kelly Hodgkins
Kelly's been writing online for ten years, working at Gizmodo, TUAW, and BGR among others. Living near the White Mountains of…
Students who use AI every day may be falling behind, while moderate users pull ahead
New global testing data suggests more AI in the classroom isn't automatically better.
Logo, Text

I assumed more AI access might help students learn faster. However, a new OECD study dispels that misconception for me and everyone else who gave their children a paid version of AI chatbots, thinking it would help them through their educational journey. 

According to PISA 2025 data from 760,000 students in 91 countries, students who use AI daily score meaningfully worse on standardized tests than their peers. The full picture is more complicated than a simple ban would fix.

Read more
XPENG just put its humanoid robot on the production line, and it walked itself out
IRON clocks in for its first shift
XPENG Iron

XPENG’s humanoid robot has officially joined the workforce, and it even got an employee badge. The Chinese automaker announced on September 8 that its next-generation IRON had completed assembly and autonomously walked off its newly commissioned humanoid robot production line in Guangzhou.

CEO He Xiaopeng then pinned a staff badge onto the robot, symbolically welcoming it to the XPENG team. It is a charming little ceremony for a machine that the company hopes will eventually become a regular part of everyday life. XPENG is moving IRON beyond R&D prototypes toward production-line manufacturing, applying the quality-control systems and manufacturing experience it has developed through its electric vehicle business.

Read more
An AI-designed drug might help slow aging, but we’re not there yet
The results hint at a possible anti-aging effect, but there’s still a long way to go before we know what it means.
medical test tubes

Rentosertib, a drug Insilico Medicine designed almost entirely using AI, was created to treat idiopathic pulmonary fibrosis, a disease that scars and stiffens the lungs over time. But fighting lung disease was only half the plan from the start.

According to a new study published in Nature Biotechnology, the drug's target was chosen specifically because it overlaps heavily with the biology of aging, and the whole trial was designed to test whether treating the lungs could also mean turning back the body's biological clock.

Read more